Reduction of DNM2 by systemic delivery of ASOs was shown to rescue myotubular myopathy in 3-week-old Mtm1−/y mice in a dose–response manner (Tasfaout et al., 2017; Koch et al., 2020). This evidence concerns the gene MTM1 and centronuclear myopathy.